Related Experiment Video
Updated: Feb 20, 2026
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
From hypertension to heart failure: update on the management of systolic and diastolic dysfunction
1Department of Medicine, Robert Wood Johnson Medical School, One Robert Wood Johnson Place, Room MEB-491, New Brunswick, NJ 08903, USA. kostis@umdnj.edu
Insights
As the US population ages, heart failure (HF) cases will rise. Early intervention and prevention of cardiovascular disease, including the use of beta-blockers, are crucial for improving patient survival rates.
Area of Science:
- Cardiology
- Geriatric Medicine
- Public Health
Background:
- The aging US population is increasing the incidence of coronary heart disease and heart failure (HF).
- HF presents a significant economic and medical burden, necessitating optimized cardiovascular (CV) disease prevention.
- HF is often the final stage of progressive CV disease, stemming from hypertension or myocardial infarction (MI).
Purpose of the Study:
- To emphasize the importance of optimizing primary and secondary prevention strategies for cardiovascular disease.
- To highlight the role of interventions at all stages of the CV continuum.
- To discuss the established benefits of beta-blockers in managing HF.
Main Methods:
- Review of existing literature on cardiovascular disease progression and heart failure.
- Analysis of the impact of cardiovascular risk factors on disease development.
- Examination of clinical trial data on the efficacy of beta-blockers in HF patients.
Main Results:
- Cardiovascular disease progresses through stages, beginning with risk factors and potentially leading to HF.
- Heart failure has a poor prognosis, with a 5-year survival rate of approximately 25%.
- Large-scale trials confirm that beta-blockers significantly reduce morbidity and mortality in patients with HF.
Conclusions:
- Optimizing prevention and early intervention are critical for managing the growing burden of heart failure.
- Beta-blockers are recommended agents shown to improve outcomes for patients with heart failure.
- Further research is needed to refine optimal cardioprotective therapies for HF.
Abstract:
The aging of the population of the United States (US) will bring with it higher numbers of patients with coronary heart disease and heart failure (HF). Because HF already imposes severe economic and medical burdens on our health care system, it is imperative to optimize primary and secondary prevention of cardiovascular (CV) disease. In most cases, HF develops as a result of either long-standing hypertension or a myocardial infarction (MI). Other than cardiac death, HF represents the last stage in the progression of CV disease, which begins with CV risk factors such as hypertension, dyslipidemia, obesity, and smoking. These risk factors lead to the development of left ventricular (LV) hypertrophy or an MI (or both), which lead to LV dysfunction and, finally, to HF. The prognosis of HF is poor, the 5-year survival rate being approximately 25%. Heart failure may be due to either LV systolic or diastolic dysfunction, the latter having a normal ejection fraction. Because CV disease is progressive, interventions are possible at all stages along the CV continuum. Beta-blockers (betaB) are recommended agents at several stages of CV disease. Large-scale trials have shown that betaB significantly reduce risks for morbidity and mortality in patients with HF. Ongoing studies should help to clarify further the optimal cardioprotective therapies in patients with HF.
More Related Videos
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
01:22Heart Failure VI: Adjunct Therapies
01:30Heart Failure V: Medical Management
01:29Heart Failure II: Pathophysiology
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure Drugs: Diuretics